ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.

Bone Marrow Transplantation
Madlen JentzschSebastian Schwind

Abstract

Secondary or therapy-related acute myeloid leukemia (s/tAML) differs biologically from de novo disease. In general s/tAML patients have inferior outcomes after chemotherapy, compared to de novo cases and often receive allogeneic stem cell transplantation (HSCT) for consolidation. The European LeukemiaNet (ELN) risk stratification system is commonly applied in AML but the clinical significance is unknown in s/tAML. We analyzed 644 s/tAML or de novo AML patients receiving HSCT. s/tAML associated with older age and adverse risk, including higher ELN risk. Overall, s/tAML patients had similar cumulative incidence of relapse (CIR), but higher non-relapse mortality (NRM) and shorter overall survival (OS). In multivariate analyses, after adjustment for ELN risk and pre-HSCT measurable residual disease status, disease origin did not impact outcomes. Within the ELN favorable risk group, CIR was higher in s/tAML compared to de novo AML patients likely due to a different distribution of genetic aberrations, which did not translate into shorter OS. Within the ELN intermediate and adverse group outcomes were similar in de novo and s/tAML patients. Thus, not all s/tAML have a dismal prognosis and outcomes of s/tAML after allogeneic HSCT in r...Continue Reading

References

Aug 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
Mar 13, 2009·Haematologica·Nicolaus KrögerUNKNOWN Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of European Group for Blood and Marrow Transpl
May 16, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard A Larson
Jan 1, 2015·Blood·R Coleman LindsleyBenjamin L Ebert
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lene Sofie Granfeldt ØstgårdJan Maxwell Nørgaard
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner
Jul 20, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey E LancetBruno C Medeiros
Dec 14, 2018·Leukemia·Wendelien ZeijlemakerGerrit J Schuurhuis
Mar 2, 2019·British Journal of Haematology·Nicolaus KrögerUNKNOWN Chronic Malignancies Working Party of the European Society for Blood Marrow Transplantation

❮ Previous
Next ❯

Citations

Jul 22, 2021·American Journal of Hematology·Juliane GrimmSebastian Schwind

❮ Previous
Next ❯

Software Mentioned

R

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.